Retrospective analysis reveals improved survival for myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms after allo-HSCT, indicating need for further advances.
Key Points
The aim is to analyze survival trends after allogeneic transplantation in patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Conducted a nation-wide retrospective study of allo-HSCT patients from 1998 to 2022.
Included patients diagnosed with de novo MDS, MDS/MPN, or therapy-related MDS and MDS/MPN.
Utilized Cox proportional hazards models for overall survival and Fine and Gray's models for relapse and non-relapse mortality.
Among 7175 patients, overall survival significantly improved over time for early and advanced MDS patients.
The number of allo-HSCT procedures increased, especially in patients aged 60 and older.
No improvement in cumulative incidence of relapse was noted across the periods.